Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

P Goetz

Showing results (301-310 of 397) with videos related to

Pageof 40
Sort By:
Molecular Endocrinology (Baltimore, Md.)|March 23, 2013
TSPYL5 SNPs: association with plasma estradiol concentrations and aromatase expressionMohan Liu, James N Ingle, Brooke L Fridley, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 10, 2021
Characteristics and Spatially Defined Immune (micro)landscapes of Early-stage PD-L1-positive Triple-negative Breast CancerJodi M Carter, Mei-Yin C Polley, Roberto A Leon-Ferre, et al.
Cancers|August 28, 2020
Perspectives on Triple-Negative Breast Cancer: Current Treatment Strategies, Unmet Needs, and Potential Targets for Future TherapiesGagan K Gupta, Amber L Collier, Dasom Lee, et al.
Cancer Discovery|June 15, 2013
Selective estrogen receptor modulators and pharmacogenomic variation in ZNF423 regulation of BRCA1 expression: individualized breast cancer preventionJames N Ingle, Mohan Liu, D Lawrence Wickerham, et al.
Breast Cancer Research and Treatment|September 16, 2017
Impact of histopathology, tumor-infiltrating lymphocytes, and adjuvant chemotherapy on prognosis of triple-negative breast cancerRoberto A Leon-Ferre, Mei-Yin Polley, Heshan Liu, et al.
Pharmacogenetics and Genomics|May 17, 2018
Germline genome-wide association studies in women receiving neoadjuvant chemotherapy with or without bevacizumabJames N Ingle, Krishna R Kalari, Donald Lawrence Wickerham, et al.
Cancer Research|October 21, 2016
Genetic Polymorphisms in the Long Noncoding RNA MIR2052HG Offer a Pharmacogenomic Basis for the Response of Breast Cancer Patients to Aromatase Inhibitor TherapyJames N Ingle, Fang Xie, Matthew J Ellis, et al.
JAMA Oncology|June 27, 2024
Tumor-Infiltrating Lymphocytes in Patients With Stage I Triple-Negative Breast Cancer Untreated With ChemotherapyVeerle C M Geurts, Sara Balduzzi, Tessa G Steenbruggen, et al.
Frontiers in Oncology|February 28, 2022
Abemaciclib in Combination With Endocrine Therapy for Patients With Hormone Receptor-Positive, HER2-Negative Metastatic Breast Cancer: A Phase 1b StudySara M Tolaney, Muralidhar Beeram, J Thaddeus Beck, et al.
Oncogene|March 6, 2021
Aurora-A kinase oncogenic signaling mediates TGF-β-induced triple-negative breast cancer plasticity and chemoresistanceMohammad Jalalirad, Tufia C Haddad, Jeffrey L Salisbury, et al.
Pageof 40

Showing results (301-310 of 397) with videos related to

Sort By:
Pageof 40
Molecular Endocrinology (Baltimore, Md.)|March 23, 2013
TSPYL5 SNPs: association with plasma estradiol concentrations and aromatase expressionMohan Liu, James N Ingle, Brooke L Fridley, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 10, 2021
Characteristics and Spatially Defined Immune (micro)landscapes of Early-stage PD-L1-positive Triple-negative Breast CancerJodi M Carter, Mei-Yin C Polley, Roberto A Leon-Ferre, et al.
Cancers|August 28, 2020
Perspectives on Triple-Negative Breast Cancer: Current Treatment Strategies, Unmet Needs, and Potential Targets for Future TherapiesGagan K Gupta, Amber L Collier, Dasom Lee, et al.
Cancer Discovery|June 15, 2013
Selective estrogen receptor modulators and pharmacogenomic variation in ZNF423 regulation of BRCA1 expression: individualized breast cancer preventionJames N Ingle, Mohan Liu, D Lawrence Wickerham, et al.
Breast Cancer Research and Treatment|September 16, 2017
Impact of histopathology, tumor-infiltrating lymphocytes, and adjuvant chemotherapy on prognosis of triple-negative breast cancerRoberto A Leon-Ferre, Mei-Yin Polley, Heshan Liu, et al.
Pharmacogenetics and Genomics|May 17, 2018
Germline genome-wide association studies in women receiving neoadjuvant chemotherapy with or without bevacizumabJames N Ingle, Krishna R Kalari, Donald Lawrence Wickerham, et al.
Cancer Research|October 21, 2016
Genetic Polymorphisms in the Long Noncoding RNA MIR2052HG Offer a Pharmacogenomic Basis for the Response of Breast Cancer Patients to Aromatase Inhibitor TherapyJames N Ingle, Fang Xie, Matthew J Ellis, et al.
JAMA Oncology|June 27, 2024
Tumor-Infiltrating Lymphocytes in Patients With Stage I Triple-Negative Breast Cancer Untreated With ChemotherapyVeerle C M Geurts, Sara Balduzzi, Tessa G Steenbruggen, et al.
Frontiers in Oncology|February 28, 2022
Abemaciclib in Combination With Endocrine Therapy for Patients With Hormone Receptor-Positive, HER2-Negative Metastatic Breast Cancer: A Phase 1b StudySara M Tolaney, Muralidhar Beeram, J Thaddeus Beck, et al.
Oncogene|March 6, 2021
Aurora-A kinase oncogenic signaling mediates TGF-β-induced triple-negative breast cancer plasticity and chemoresistanceMohammad Jalalirad, Tufia C Haddad, Jeffrey L Salisbury, et al.
Pageof 40